| Literature DB >> 30013372 |
Nima Pourhabibi Zarandi1, Guillermo Galdon1, Stanley Kogan1,2, Anthony Atala1,2, Hooman Sadri-Ardekani1,2.
Abstract
While the survival rate of children with cancer is increasing, preserving fertility for prepubertal boys is still a challenge. Although intracytoplasmic sperm injection (ICSI) using frozen sperms has revolutionized infertility treatment, it is not applicable for the patients who undergo chemotherapy before puberty since spermatogenesis has not begun. Therefore, preserving spermatogonial stem cells (SSCs) as an experimental option can be provided to prepubertal patients at a risk of damage or loss of their SSCs due to cancer treatments and developmental or genetic disorders. Using frozen SSCs in testicular tissue, successful SSC autotransplantation in mouse and nonhuman primates has shown a promising future for SSC-based cell therapy. Cryopreservation of testicular tissue containing SSCs is the first step to translate SSC-based cell therapy into clinical male infertility treatment, and in the investigation into SSCs, it is very important to evaluate their quantity and functionality during this process. This systematic review summarizes the published data on cryopreservation techniques in human testis tissue for potential utilization in future clinical applications.Entities:
Keywords: cryopreservation; male infertility; spermatogonial stem cell; testis; tissue banking; transplantation
Year: 2018 PMID: 30013372 PMCID: PMC6039063 DOI: 10.2147/SCCAA.S137873
Source DB: PubMed Journal: Stem Cells Cloning ISSN: 1178-6957
Figure 1Potential future clinical applications using stored testicular tissue from high-risk patients. I. isolation and in vitro propagation of SSCs to have adequate number of SSCs for transplantation. Patients will try for natural conception or IVF/ICSI. II. Isolation of testicular cells and in vitro differentiation of cells into sperms and use in IVF/ICSI. III. Ex vivo culturing of testicular tissue to differentiate SSCs to sperms and use in IVF/ICSI. IV. Xenografting of cryopreserved tissue under the skin at the back of mouse until they differentiate to sperms and are used for ICSI/IVF. These options are all experimental and not clinically available.
Abbreviations: ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilization; SSCs, spermatogonial stem cells.
Figure 2Article selection flowchart.
Figure 3Different methods for cryopreservation of testicular tissue. (A) Nalgene® Mr. Frosty® container using isopropyl alcohol and (B) CoolCell® cell-freezing container without alcohol, both (A and B) with a cooling rate of −1°C/min. (C) Programmable control rate freezer that can be programmed by software for customized cooling rates. (D) Vitrification; showing vitrification rod (cryostraw) and solutions (scale bar =5 mm).
Summary of all studies that were included in this systematic review
| Year | Study | Number of patients | Indication | Patients’ age range (year) | Frozen material | Freezing method | Cryoprotectant |
|---|---|---|---|---|---|---|---|
| 2000 | Bahadur et al | 2 | Oncology | 8 and 13 | Tissue | Liquid nitrogen vapor phase | Glycerol |
| 2001 | Brook et al | 5 | Infertility | 22–35 | Isolated cells | CRF | DMSO, 1,2-propanediol, ethylene glycol, glycerol |
| 2005 | Keros et al | 16 | Unclear | 27–42 | Tissue | CRF | Glycerol, PrOH, and DMSO |
| 2006 | Kvist et al | 8 | Cryptorchidism | 1–5 | Tissue | CRF | Ethylene glycol |
| 2007 | Keros et al | 5 | Oncology | 2–14 | Tissue | CRF | DMSO |
| 2007 | Wyns et al | 11 | Cryptorchidism | 2–12 | Tissue | CRF | DMSO |
| 2008 | Wyns et al | 5 | Hematology/oncology | 7–14 | Tissue | CRF | DMSO |
| 2009 | Sadri-Ardekani et al | 6 | Orchiectomy (prostate cancer) | N/A | Tissue | Insulated container in a −80°C freezer | DMSO |
| 2010 | Ginsberg et al | 14 | Oncology | 0.25–14 | Tissue | CRF | DMSO |
| 2011 | Van Saen et al | 4 | Hematology/oncology | 3, 5,12, and 13 | Insulated container in a −80°C freezer | DMSO | |
| 2011 | Sadri-Ardekani et al | 2 | Oncology | 6.5 and 8 | Tissue | CRF | DMSO |
| 2011 | Wyns et al | 62 | Hematology/oncology | <12 and 12–16 | Tissue | CRF | DMSO |
| 2011 | Curaba et al | 2 | Oncology | 6 and 12 | Tissue | CRF and vitrification | DMSO and ethylene glycol |
| 2012 | Stimpfel et al | 6 | Azoospermia | 21–41 | Tissue | CRF | Glycerol |
| 2012 | Van Saen et al | 7 | Klinefelter syndrome | 13–16 | Tissue | Insulated container in a −80°C freezer | DMSO |
| 2013 | Mirzapour et al | 8 | Infertility | 28–50 | Isolated cells | Insulated container in a −80°C freezer | DMSO |
| 2013 | Pacchiarotti et al | 5 | Orchiectomy (transgender) | 25–40 | Isolated cells/tissue | CRF | PBS + 10% HSA + 10% DMSO/1% dextran |
| 2013 | Van Saen et al | 6 | Hematology/oncology | 2.5–12.5 | Tissue | Insulated container in a −80°C freezer | DMSO |
| 2013 | Poels et al | 10 | Hematology/oncology | 2–12 | Tissue | CRF and vitrification | DMSO and ethylene glycol |
| 2013 | Baert et al | 14 | Vasectomy reversal | N/A | Tissue | Slow Freezing container, CRF, and vitrification | DMSO and ethylene glycol |
| 2014 | Nickkholgh et al | 2 | Orchiectomy (prostate cancer) | N/A | Tissue | Insulated container in a −80°C freezer | DMSO |
| 2014 | Zheng et al | 9 | Orchiectomy (brain dead donors) | 13–40 | Tissue | N/A | DMSO |
| 2014 | Nickkholgh et al | 2 | Orchiectomy (prostate cancer) | N/A | Tissue | Insulated container in a −80°C freezer | DMSO |
| 2015 | Pietzak et al | 27 | Hematology/oncology | 2.2–11.5 | Tissue | CRF | DMSO |
| 2015 | Baert et al | 6 | Vasectomy reversal/orchiectomy (prostate cancer) | N/A | Tissue | Slow freezing container | DMSO |
| 2016 | Sadri-Ardekani et al | 23 | Oncology/cryptorchidism | 0.7–16 (oncology), 1.4–11 (cryptorchidism) | Tissue | CRF (sperm, stem) | DMSO and glycerol |
| 2016 | Medrano et al | 3 | Orchiectomy (prostate cancer) | N/A | Tissue | Insulated container in a −80°C freezer | DMSO |
| 2017 | Gat et al | 2 | Orchiectomy (testicular malignancy, testicular pain) | 25 and 32 | Tissue | N/A | MEM + 20% FBS + 5% DMSO |
| 2017 | de Michele et al | 3 | Oncology | 2, 11, and 12 | Tissue | CRF | DMSO |
| 2017 | Pendergraft et al | 3 | Orchiectomy (brain dead donors) | 56–61 | Tissue, 3D organoid | Insulated container in a −80°C freezer | DMSO |
Abbreviations: CRF, control rate freezer; DMSO, dimethyl sulfoxide; FBS, fetal bovine serum; HSA, human serum albumin; MEM, minimum essential media; PBS, phosphate-buffered saline; PrOH, propane-1,2-diol; N/A, not available.
Comparison of control rate freezer programs used in different studies for spermatogonial stem cell cryopreservation
| Year | Author | Cryoprotectant | Start | Step 1 | Step 2 | Step 3 | Step 4 | Step 5 | Step 6 | Step 7 | Step 8 | Step 9 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2001 | Brook et al | DMSO 1.5 M | 20°C | −2°C /min to 4°C | −0.3°C / min to −30°C | −50°C /min to −180°C | Liquid N2 (−196°C) | – | – | – | – | – |
| 1,2-Propanediol 1.5 M | ||||||||||||
| Glycerol 1.5 M | ||||||||||||
| Ethylene glycol 1.5 M | ||||||||||||
| 2005 | Keros et al | 1,2-Propanediol | 22°C | −2°C /min to −6°C | −6°C hold 10 minutes | −0.3°C /min to −35°C | −35°C hold 5 minutes | −35°C to −70°C | Liquid N2 (−196°C) | – | – | – |
| Glycerol | 22°C | −8°C /min to −6°C | −5°C /min to −30°C | −30°C hold 15 minutes | −4°C /min to −43°C | Liquid N2 (−196°C) | – | – | – | – | ||
| DMSO | −1°C /min to 0°C | 0°C hold 5 minutes | −0.5°C /min to −8°C | −8°C hold 15 minutes | −0.5°C /min to −40°C | −40°C hold 10 minutes | −7°C /min to −80°C | Liquid N2 (−196°C) | – | |||
| 2006 | Kvist et al | Leibovitz L-15 medium + 1.5 mol/L ethylene glycol + 0.1 mol/L sucrose +10 mg/ml HSA | 1°C | −2°C /min to −9°C | Soaking 5 minutes | −0.3°C /min to −40°C | −10°C / min to −140°C | Liquid N2 (−196°C) | – | – | – | – |
| PBS + 1.5 mol/L ethylene glycol + 0.1 mol/L sucrose +10 mg/ mL HSA | ||||||||||||
| 2007 | Keros et al | DMSO 5% + HSA 5% | 4°C | −1°C /min to 0°C | 0°C hold 5 minutes | −0.5°C /min to −8°C | −8°C hold 10 minutes | −0.5°C /min to −40°C | −40°C hold 10 minutes | −7°C /min to −70°C | Liquid N2 (−196°C) | – |
| −1°C /min to −8°C | −8°C hold 10 minutes | −10°C /min to −80°C | Liquid N2 (−196°C) | – | – | – | – | – | ||||
| 2007, 2008, 2011 | Wyns et al | DMSO 0.7 mol/L + sucrose 0.1 mol/L + HSA 10 mg/mL | 4°C | 0°C hold 9 minutes | −0.5°C / min to −8°C | −8°C hold 20 minutes | −0.5°C / min to −40°C | −40°C hold 10 minutes | −7°C /min to −80°C | Liquid N2 (−196°C) | – | – |
| 2011 | Curaba et al | |||||||||||
| 2012 | Stimpfel et al | Glycerol | 20°C | −5°C /min to −6°C | −10°C /min to −30°C | −20°C /min to −140°C | Liquid N2 (−196°C) | – | – | – | – | – |
| 2013 | Pacchiarotti et al | 10% HSA + 10%DMSO/1% dextran | 4°C | 4°C hold 10 minutes | −1°C /min to −80°C | −50°C /min to −120°C | Liquid N2 Vapor Phase (−188°C) | – | – | – | – | – |
| 2016 | Sadri-Ardekani et al | Sperm freezing media test yolk buffer | 20°C | 20°C hold 20 minutes | −1°C /min to 5°C | −10°C /min to −80°C | −25°C / min to −130°C | Liquid N2 (−196°C) | – | – | – | – |
| 5% HSA + 5% DMSO | 4°C | 4°C hold 30 minutes | −1°C /min to 0°C | 0°C hold 5 minutes | −0.5°C / min to −8°C | −8°C hold 10 minutes | −0.5°C /min to −40°C | −40°C hold 10 minutes | −7°C / min to −70°C | Liquid N2(−196°C) |
Abbreviations: DMSO, dimethyl sulfoxide; HSA, human serum albumin; PBS, phosphate-buffered saline.